SUMMARY Developments relating to cobalamin and folate are reviewed. Current work on the relations between these two coenzymes are discussed, particularly those that have emerged in studies using nitrous oxide, which inactivates cobalamin. This review covers the developments of the past quarter century and how the ideas of 25 years ago have stood the test of time.
During the 1960s many ideas were developed about the megaloblastic anaemias. Cobalamin assays on human sera, initially at the Royal Postgraduate Medical School, had been consolidated, and patients with megaloblastic anaemia could be grouped into those with low B12 concentrations and those with normal concentrations.' Isotopically labelled B,2 became available and B,2 absorption tests became part of clinical practice.2 A method for the assay of serum folate was described3 and was quickly extended to the more useful red cell folate assay. 4 By the end of 1963 an assay for the intrinsic factor content of gastric juice5 6and for the detection of antibodies in serum to intrinsic factor had been introduced as well as methods for detecting gastric parietal cell antibodies.
The use of urinary formiminoglutamic acid (Figlu) as a test for folate deficiency reared its ugly head. 7 And, finally, two groups put forward a hypothesis to account for the strange interrelation between B12 and folate that came to be known as the methylfolate trap hypothesis. 8 9 This review covers the developments of the past quarter century and how the ideas of 25 years ago have stood the test of time.
Automated cel counters and mean corpuscular volume
The introduction into haematology laboratories of accurate and sophisticated blood counting machines is the major technical development of the past 25 years. It has highlighted the value of red cell size (mean corpuscular volume, MCV) in diagnosis and emphasised the raised MCV in many disorders that are unrelated to impairment of B,2 and folate metabolism. Normoblastic macrocytosis occurs in chronic alcoholism, hypothyroidism, normal pregnancy, healthy neonates, marrow failure, chronic haemolytic states with raised reticulocyte values, many preleukaemic (myelodysplastic) disorders, and treatment with many cytotoxic drugs including, chlorambucil, mephalan, methotrexate, azathioprine etc. Finally, there is a common macrocytosis occurring in premenopausal women whose only complaint is lassitude, which remains unexplained.
Not all patients with megaloblastic anaemia will have an increased MCV. Some who have thalassaemia trait, anaemia of chronic disorders, or concurrent iron deficiency may have a frankly megaloblastic marrow with a normal MCV."0 When treated with B,2 or folate, or both, the MCV falls to that associated with the underlying disorder below the normal range of 80 to about 94 fl.
Finally, there is no agreement as to what constitutes the normal MCV: quoted ranges vary from 76 at the lower end to 108 fl at the upper end. This is because there is no absolute way to obtain this value and the machine methods relate to the manner in which the settings are manipulated.
The serum cobalamin (B12) concentration
The early assays for B12 were all microbiological assay procedures, and in essence these gave similar results. The assays were tedious to perform and often assays were rejected because of loss of purity of the organism, introduction of extraneous B,2 in the assay system, and poor growth of the assay organism. For these reasons the development of an alternative method based on dilution of isotopically labelled B,2 by the native B,2 in a serum sample (saturation analysis) was widely welcomed. These assays lent themselves to the preparation of commercial kits that have become the mainstay of laboratory assays.
It soon became apparent that often a lot more B,2 was being measured by the isotope methods than microbiological methods." -'3 Thus the lower limit of the normal range could be 300 pg/ml with an isotope assay but was about 170 pg/ml by microbiological assay. A value of 250 pg/ml was low by isotope assay but plumb normal when assayed microbiologically.
When have cooked the B12 with egg and served up an aliquot of this material.21 The test thus requires digestive processes to release B12 from this unpromising material so that it can bind to intrinsic factor, which in turn will enable B12 to be absorbed. Even normal subjects are unable to achieve normal B12 absorption with this method, the mean urinary excretion with egg white being between 2-7 to 4 0% of a 1-68 ig oral dose and 5 1 to 6-0 with egg yolk. By contrast, the mean result in the standard Schilling test was 23-6%. Normal has been defined as the B12 absorption of aqueous B12 or absorption of food B12 as natural B12 in lamb.22 Not surprisingly, achlorhydric patients and patients after gastric surgery fare even worse than controls with protein bound B12. This is presumably because they cannot activate pepsinogen to aid proteolytic digestion of the binding proteins. The test has been interpreted, however, as detecting a lack of intrinsic factor at a stage when the standard B12 absorption test is still normal. There are no available data to suggest that this is likely; nor is there any evidence that the test is of any clinical value.
Dietary B12 is present either as part of methionine synthetase or as part of methylmalonyl CoA-mutase. Small amounts are linked to R-binders. Once B12 is released from the holoenzyme, much of it links to Rbinder mainly from saliva, although R-binder is also present in gastric and intestinal juice. Pancreatic enzymes serve to release B12 from its R-binder link and permit its uptake by intrinsic factor. In pancreatitis B12 absorption is impaired because of failure to degrade the R-binder. Brugge The problem in developing such an assay is that gastric juice has at least three B12 binding proteins: intrinsic factor, partially digested intrinsic factor, and R-binder. When labelled B12 is added to gastric juice some binds to all three components, hence the binding of B12 alone cannot be used as a measure of intrinsic factor. Each of these binding proteins, however, can be prevented from taking up B12. An intrinsic factor antibody present in serum in more than half the patients with pernicious anaemia, and when added to gastric juice, will react with intrinsic factor and prevent B12 uptake by intrinsic factor. Thus B12 binding is now due only to R-binder, and when this value is subtracted from the total B12 binding of gastric juice, it is a measure of intrinsic factor content. One unit of intrinsic factor is the amount binding I ng of B12.
Cobinamide is a B12 analogue that lacks the benzimidazole moiety. It binds firmly to R-binder but not at all to intrinsic factor. Addition of cobinamide to gastric juice will block the R-binder, so that subsequent addition of labelled B12 will bind only to intrinsic factor. 24 Assay of intrinsic factor has confirmed its virtual disappearance in pernicious anaemia; there is a vast excess present in healthy subjects. Only 1% of the normal daily output is required for normal B12 absorption.10 Finally, abnormal forms of intrinsic factor have been shown in megaloblastic anaemia in infancy-that is, these have bound labelled B12 but have failed to potentiate its intestinal absorption. 25 Detection of antibody to intrinsic factor is a useful aid in diagnosis of pernicious anaemia but, rarely, this antibody can be present in patients with Graves' disease, atrophic gastritis etc in the absence of pernicious anaemia.26 More than 40% of patients with pernicious anaemia, however, do not have such an antibody in serum but may have it in the gastric secretion, when it is likely to be an IgA immunoglobulin rather than a IgG as in serum. Even those who lack humoral antibody against intrinsic factor generally show evidence of cell mediated immunity against intrinsic fac-tor." The importance of cell mediated immunity is shown by the high incidence of pernicious anaemia in patients with acquired hypogammaglobulinaemia, 30% of whom develop the disease.'0 These patients are unable to form humoral antibodies. These intrinsic factor antibodies are able to neutralise residual intrinsic factor secretion, or damage intrinsic factor secreting cells and convert a just adequate B12 absorption (present in simple atrophic gastritis) to an inadequate one so that a strong negative B,2 balance develops. This is soon followed by clinically overt pernicious anaemia. Marrow cells from megaloblastic patients are unable to methylate deoxyuridine as well as normal cells, and less than 90% is used and more than 10%
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[3H]thymidine is taken up into DNA. If B12 is added to a further aliquot of marrow cells there is some correction of the impairment in B12 deficient marrows but no correction with those deficient in folate. Formyltetrahydrofolate (such as folinic acid) will correct the impairment in both B,2 and folate deficiency.
The dU suppression test is a test for "megaloblastosis" and provides an indication of the nature of the deficiency when it is combined with addition of B,2 or folate to the incubation mixtures. It is, how-982 ever, time consuming, the manipulations taking the better part of a day.
Cobalamin-folate interrelations
The methylfolate trap hypothesis to explain B12 folate interrelations was proposed just over 25 years ago.8 9 Both B12 and folate are required for the synthesis of methionine (fig 2) . The methyl group from methylfolate is passed on to homocysteine to form methionine, and B12 is an intermediary in this transfer. In the absence of B12 this pathway is interrupted. Two further observations led to the formulation of the methylfolate trap hypothesis.
1 The thermodynamics of the reaction by which methylfolate is formed from methylenefolate (5, 10, CH2 folate-e 5-CH3 folate) is strongly shifted to the right-that is, on the basis of in vitro studies it was concluded that once methylfolate was formed it was improbable that it could be oxidised back to methylenefolate. 2 In untreated pernicious anaemia the serum folate (largely methylfolate) is increased. It was therefore deduced that in B12 deficiency methylfolate could not be used, it could not be oxidised back to methylenefolate, and as more folate accumulated in the methyl form a shortage of other folate analogues emerged. It was consequently supposed that there was impaired transfer of formyl for purine synthesis and methylene transfer for thymidine synthesis and that this led to interference with DNA synthesis and megaloblastosis. The raised serum folate was cited as supporting methylfolate trapping.
These views have been difficult to test as patients with untreated pernicious anaemia do not readily lend themselves to the sort of study required.
The situation was transformed by the observation that the anaesthetic gas nitrous oxide (N20) is activated by organometallic complexes of which B12 is the prime example.33 N20 is cleaved and at the same time B12 is oxidised to an irreversibly inert form. N20, in fact, specifically inactivates the enzyme methionine synthetase, of which B12 is a coenzyme.34 Exposure to N20 rapidly produces "B12 deficiency."
In man this can lead to megaloblastic anaemia, neuropathy, and even death. Other species do not become megaloblastic, but some like the monkey and probably fruit bats develop a neuropathy. All, however, develop very similar biochemical changes, and these have now been studied in some depth. It is now possible to assess the validity of the premises on which the methylfolate trap hypothesis was formulated. ferred to homocysteine in B12 deficiency there is impaired use of methylfolate. Thus in the dU suppression test methylfolate did not correct the defect in B12 deficient marrow cells. Neither in marrow cells from pernicious anaemia nor from rats treated with N20, however, was tetrahydrofolate itself able to correct the defect in thymidine synthesis, although formylfolate was fully active.35 This is quite an unexpected result from the point of view of the methylfolate trap hypothesis as tetrahydrofolate is outside the trap.
The same pattern of results emerged when the form of folate used by liver for making folate polyglutamate was studied. Normal rat liver used all folate analogues equally for making the polyglutamate. When B12 was inactivated by N20, however, no polyglutamate at all was made from methylfolate and tetrahydrofolate, but normal amounts from formylfolate. 36 Failure to use tetrahydrofolate and the normal use of formyltetrahydrofolate are not predicted by methylfolate trapping. Rather they suggest a role for B12 in the formylation of folate.
IS THE IN VITRO PREDICTION THAT METHYLFOLATE CANNOT BE OXIDISED BACK TO METHYLENE AND FORMYLFOLATE CORRECT IN IN VIVO?
One of the two papers in 1961 that formulated the methylfolate trap theory also contained the seeds for its destruction.8 Noronha and Silverman found that 1% methionine added to the diet and fed for 24 hours to rats before sacrifice resulted in a considerable decline in the methylfolate concentrations in liver while increasing the formylfolate and tetrahydrofolate content. This occurred in both control and B12 deficient rats. This implies oxidation of the methyl group to formyl and to carbon dioxide. This has been confirmed many times since. Brody etal37 showed that this occurred within 30 minutes of an injection of methionine and that the methyl group oxidation occurred on folate hexaglutamate.
The amount of methionine needed to promote oxidation of the methyl group of methylfolate was as little as 0 5 pmol. S-adenosylmethionine was less active than methionine and seemed to be active only through its further metabolism to methionine. Thus the hepatic concentration of methylfolate is regulated by that of methionine in both normal and B12 deficient animals.
Other observations also point to in vivo oxidation of the methyl moiety of methylfolate. Methylfolate can serve as the methyl donor in the methylation of biogenic amines. 38 The mechanism entails the oxidation of the methyl group to formate, which in turn is transferred to the biogenic amine. The enzyme responsible for the oxidation of the methyl group was the same one concerned with its formation-namely, methylenetetrahydrofolate reductase38
Furthermore, Thorndike and Beck39 reported that the methyl group of methylfolate was oxidised in an essentially similar manner by lymphocytes from both normoblastic controls and one patient with pernicious anaemia.
WHAT IS THE PATHWAY FOR OXIDATION OF THE METHYL GROUP OF METHYLFOLATE IN B12 DEFICIENCY?
Lumb et al40 showed that in B12 inactivated rats where the methyl group could not be transferred to homocysteine, methyltetrahydrofolate itself was used as the substrate for forming methylfolatepolyglutamate. When methylfolate labelled with ['4CJ in the methyl group was used ["4C]-labelled polyglutamates containing 3, 4, and 5 glutamic acid residues were identified. As no polyglutamate with the [14CJ label having 6 glutamic acid was present it was concluded that the methyl group was oxidised from the hexaglutamate.
Methionine and cobalamin-folate function Not only are both folate and cobalamin required for methionine synthesis, but many of the effects of B12 deficiency in both man and rat are overcome to a greater or lesser degree by the provision of methionine.
In man methionine given to patients with pernicious anaemia in relapse will abolish an abnormal urinary formiminoglutamic acid excretion and, used in appropriate dose, will correct the abnormal dU suppression test. 4' In fruit bats treated with N2042 and in monkeys43 methionine will considerably improve neuropathy. In B12 inactivated rats methionine will restore to normal folatepolyglutamate synthesis.36
Even more effective than methionine, is a derivative of methionine via S-adenosylmethionine-namely, 5-methylthioadenosine.36 This compound is further metabolised to methionine and formate. Methionine can also yield formate by a second pathway-namely, oxidation of its methyl group.
How B12 deficiency affects folate metabolism
Methionine is the pivotal compound in B12 folate metabolism. Lack of B12 produces a shortage of methionine that is only partially alleviated by induction of another pathway to methylate homocysteinenamely, betaine methyltransferase whereby betaine supplies the methyl group to methylate homocysteine instead of methylfolate. Lack of methionine has two consequences: 1 Lack of single carbon units at the formate level of oxidation, which arises from both oxidation of the methyl group of methionine and via S-adenosylmethionine -+ decarboxylated S-adenosylmethionine 5-methylthioadenosine -+ 5-methylthioribose methionine plus formate. Formate is required for purine synthesis and for formation of formyltetrahydrofolate, which seems to be the preferred substrate for folate polyglutamate synthesis, and by further reduction into methylene for pyrimidine synthesis. 2 The lack of S-adenosylmethionine, as indicated, may restrict supply of formate. It may interfere with general transmethylation reactions, although a role for transmethylation in haemopoiesis has still to be shown. There is no fall in S-adenosylmethionine values in the brain in fruit bats treated with N20 and hence impaired transmethylation in brains is unlikely. Serine has been widely regarded as the main source of single carbon units largely because it is readily available by synthesis from glucose. B12 inactivation does not affect the pathways by which serine can donate a single carbon unit. Nevertheless, large doses of serine do not in any way ameliorate the effect of B12 inactivation. This must cast doubt on the importance of serine as a major single carbon unit donor.
The hypothesis that has been advanced to explain B12-folate interrelations-the formate-starvation hypothesis-postulates that B12 deficiency leads to shortage of methionine, and this in turn, to a shortage of active-formate derived from methionine.
